Jan Schnitzer
Company: Proteogenomics Research Institute For Systems Medicine
Job title: Founder, Chief Executive Officer and Institute Director
Seminars:
Reimagining Precision Delivery to Enable TGF-β Therapies at Ultra-Low, Nontoxic Doses 9:30 am
Proving how endothelium is the critical barrier to low dose precision therapeutic efficacy without toxicities New dual precision therapeutics to penetrate endothelium and to fully block TGF-β only inside the lung Transvascular pumping of drugs by design boosts site delivery and potency 1000x and circumnavigates toxicity New Data!Read more
day: Conference Day Two